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ABSTRACT
Among a total of 101 isolates from the first
systematic multicentre surveillance effort con-
cerning invasive Streptococcus pyogenes disease in
Greece, conducted between 2003 and 2005 and
covering 38% of the population, emm types 1
and 12 were prevalent, being responsible for 27
and nine cases, respectively. The isolates from the
remaining 65 cases were assigned to 26 other emm
types. Erythromycin resistance (12 isolates) was
primarily mef(A)-mediated, although all emm
type 1 strains were susceptible. Tetracycline resis-
tance, due mostly to tet(M), was detected in 26
isolates. Subtyping by pulsed-field gel electro-
phoresis yielded 50 chromosomal fingerprints,
thus discriminating further among ten of the 28
observed emm types.
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Streptococcus pyogenes, apart from causing phar-
yngitis and impetigo, causes severe invasive
disease, e.g. necrotizing fasciitis (NF) and strepto-
coccal toxic shock syndrome [1]. Since the
mid-1980s, a resurgence of invasive S. pyogenes
infections has been observed [1], coupled with an
equally worrying increase in rates of resistance
to macrolides used for treating patients with
hypersensitivity to the drug of choice, penicillin [2].
Greek invasive strains and their susceptibility
to antimicrobials had not been investigated thus
far. From 2003, within the Strep-EURO project
(http://www.strep-euro.lu.se), enhanced surveil-
lance of severe S. pyogenes infections and collec-
tion of the responsible isolates were implemented.
The results of the first 3 years of this study are
presented here.
During the period 1 January 2003 to 31 Decem-
ber 2005, 101 S. pyogenes isolates (one per patient)
from patients with invasive infections (according
to published case definitions [3]) were isolated
from blood culture (42 isolates: bacteraemia with
no focal symptoms, 19; deep tissue infection or
NF, 12; streptococcal toxic shock syndrome, six;
osteomyelitis, three; arthritis, two), abscess ⁄deep
tissue, sampling during surgery (44 isolates: NF,
18; deep tissue infections, 26), synovial fluid (seven
isolates; arthritis), pleural fluid (four isolates;
pneumonia with pleurisy), cerebrospinal fluid
(three isolates; meningitis), and bronchoalveolar
lavage (one isolate; pneumonia with pleurisy).
Patients had been hospitalized in 15 general
hospitals, 12 in the Athens metropolitan area, and
one each in northern, southern and western
Greece, covering c. 38% of the Greek population
(10 628, 113; 2001 census, http://www.statistics.
gr/StatMenu_eng.asp). Species identification was
based on standard biochemical procedures, i.e.
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the latex agglutination test for the Lancefield
group A antigen (Lorne Laboratories Ltd,
Reading, UK) and the API 20STREP (bioMerieux,
Marcy L’Etoile, France).
MICs of erythromycin, clindamycin and tetra-
cycline were determined by Etest (AB Biodisk,
Solna, Sweden), and interpreted according to
CLSI guidelines [4]. Macrolide–lincosamide–
streptogramin B (MLSB) resistance phenotypes
were assigned by the double-disk test [5]. For
PCR, crude cellular extracts were used [6]. Ampli-
fication of the mef, erm(B) and erm(A) sequences,
and mef(A) ⁄ (E) subtype assignment, were
performed as described previously [6,7].
Tetracycline-resistant isolates were tested
for tet(M) and tet(O) by multiplex PCR [8,9].
Amplification of spe(A), spe(B) and spe(C)
sequences was performed by multiplex PCR
[10]. PCR amplification and sequencing of emm
sequences, and assignment to emm types, were
performed according to the CDC protocols for
S. pyogenes (http://www.cdc.gov/biotech/strep/
protocols.htm). An optimized pulsed-field gel
electrophoresis (PFGE) protocol was derived
from four published protocols [10–12; http://www.
cdc.gov/pulsenet/protocols.htm]. SmaI-digested
or XmaI-digested genomic DNA was analyzed
by electrophoresis in 1% agarose ⁄ 0.5 · TBE in a
CHEF DRIII apparatus (Bio-Rad Laboratories,
Athens, Greece). Band patterns were compared
using GELCOMPAR software (Applied Maths, Sint-
Martens-Latem, Belgium), the Dice coefficient of
similarity, the unweighted pair group method
using arithmetic averages (UPGMA) clustering
algorithm, and a 1.5% tolerance in band position
differences. Patterns similar at 80–99% [13] (with
differences in up to four DNA fragments [14])
were assigned to different subtypes of the same
type. Statistical analysis (Fisher exact test) was
performed with INSTAT 3.0 (GraphPad Software,
San Diego, CA, USA).
All but two of the 101 isolates were assigned
to a known emm type, the most frequent types
(‡5%) being 1, 12, 4, 6 and 95 (27, nine, five,
five and five isolates, respectively) (Table 1).
emm type 1 has been shown to be the most
Table 1. Erythrogenic toxin and antibiotic resistance genes of the emm types detected among the 101 invasive Streptococcus
pyogenes isolates
emm
type
No. of
isolates
No. of isolates having an erythrogenic toxin gene profile No. of isolates resistant to
Resistance gene
(no. of isolates)spe(B) spe(B) + spe(A) spe(B) + spe(C) spe(B) + spe(C) + spe(A) Erya Teta Ery + Tet
1 27 2 22 – 3 – – – –
3 3 – 3 – – – – – –
4 5 – – 5 – 3 – – mef(A) (3)
5 2 – – 2 – – – – –
6 5 – – 5 – – – – –
11 2 – – 2 – – – – –
12 9 2 – 7 – 2 – 2 mef(A) (1)
erm(A) (1)
erm(B) + tet(M) (1)
erm(B) (1)b
19 1 1 – – – – – – –
22 3 – – 3 – – 2 – tet(O) + tet(M) (2)
29 4 3 – 1 – – – – –
50 1 – – 1 – – – – –
53 4 4 – – – – 4 – tet(M) (4)
65 3 2 – 1 – – – – –
75 3 1 – 2 – 2 – mef(A) (2)
77 3 – – 3 – – 1 2 erm(A) + tet(O) (2)
tet(O) (1)
78 1 – – 1 – – – – –
80 1 1 – – – – – – –
83 1 1 – – – – 1 – tet(M) (1)
85 3 3 – – – – 3 – tet(M) (3)
87 2 2 – – – – 2 – tet(M) (2)
89 4 2 – 2 – – – – –
95 5 5 – – – – 4 – tet(M) (4)
101 1 – – 1 – – – – –
108 1 1 – – – – 1 – tet(M) (1)
113 1 1 – – – – 1 – tet(M) (1)
115 1 – – 1 – – 1 – tet(M) (1)
117 1 1 – – – – – 1 erm(A) (1)b
118 2 – – 2 – – – – –
NT 2 – – 1 – – 1 – tet(M) (1)
Total 101 32 25 41 3 7 21 5
aEry, erythromycin; Tet, tetracycline.
bIsolate additionally resistant to tetracycline but negative for both tet(M) and tet(O).
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prevalent among invasive isolates internation-
ally, with emm type 12 also frequently being
observed [2].
All 27 emm type 1 strains were susceptible to all
antimicrobials, in contrast to the results of other
studies [15]. The 12 erythromycin-resistant
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Fig. 1. Similarity dendrogram of the 101 invasive isolates after typing by pulsed-field gel electrophoresis (PFGE). To the
right of the gel lanes are shown, in sequence, the isolate number, the emm type, and the PFGE type. DNA from all isolates
was digested by SmaI, except that of the mef(A)-containing isolates (nos 3, 5, 10, 40, 61, and 64), digested with XmaI.
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(MIC ‡1 mg ⁄L) isolates belonged to five emm
types (Table 1). Six erythromycin-resistant iso-
lates, expressing the M phenotype, harboured
mef(A), four iMLSB (inducible) phenotype isolates
harboured erm(A), and the remaining two, also
expressing high-level clindamycin resistance
(MIC >256 mg ⁄L) and the cMLSB (constitutive)
phenotype, harboured erm(B). These resistance
genes were not detected among the 89 susceptible
strains.
The erythromycin resistance rate (11.9%)
reported here is lower than those reported
in previous Greek studies (range: 15.2–38.0%),
most of which were conducted in a single area
during 1999–2000 using mostly non-invasive iso-
lates [16–19], usually found to be more resistant to
erythromycin than invasive isolates [20], although
studies indicating the contrary also exist [15,21].
The predominance of mef(A) has been reported
previously in S. pyogenes isolates from Greece and
other streptococci [16,19], suggesting that it is the
main mechanism of streptococcal resistance to
macrolides in Greece, as elsewhere [15]. This is
most probably due to mef-encoding mobile genetic
elements causing horizontal transmission among
streptococcal species [22].
Seven isolates were intermediately resistant
(MIC 4 mg ⁄L) and 19 highly resistant
(MIC ‡8 mg ⁄L) to tetracycline. This resistance
rate, similar to rates in northern and central
Europe [23], was due mostly to tet(M) rather than
tet(O) (Table 1). No differences in resistance genes
were observed between intermediately and
highly resistant isolates, although in two highly
resistant isolates, neither gene could be detected.
Only five isolates were resistant to both erythro-
mycin and tetracycline (Table 1). Whereas five
emm types were responsible for macrolide resis-
tance, tetracycline resistance was more dispersed
(12 emm types), with over 40% being attributable
to three types: 53, 85 and 95.
All isolates possessed spe(B), combined mostly
with spe(C) (44 isolates) or spe(A) (28) (Table 1).
The majority of emm type 1 (25 of 27) and all emm
type 3 isolates possessed spe(A), in contrast to the
71 isolates belonging to all other emm types
(p <0.0001), an association in agreement with
previous reports [1].
PFGE allowed assignment of all 101 isolates to
39 types: 19 (A–S) represented by two or more
isolates each, and 20 represented by a single
isolate each (unique (u) types) (Fig. 1). Eight types
(A, E, G, H, N, O, P and Q) were further divided
into two subtypes each, whereas type R contained
four subtypes. Therefore, PFGE, yielding 50 chro-
mosomal fingerprints, discriminated further
among ten of the 28 observed emm types. Con-
versely, emm types 53 and 108 were assigned to
two subtypes of type A. No association was
observed between differences detected by PFGE
among isolates of the same emm type, and any of
the other characteristics studied.
In conclusion, results from the initial 3 years
of the first enhanced surveillance of invasive
S. pyogenes, covering c. 38% of the Greek popula-
tion, showed that among the 28 emm types
observed, types 1 and 12 prevailed. Erythromycin
resistance, mostly mef(A)-mediated, was less
frequent than that reported previously for
non-invasive isolates in Greece. Nevertheless,
the principal emm type 1 clone still remains
uniformly susceptible.
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